Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix®) in renal transplant recipients
S Brakemeier, B Schweiger… - Nephrology Dialysis …, 2012 - academic.oup.com
S Brakemeier, B Schweiger, N Lachmann, P Glander, C Schönemann, F Diekmann…
Nephrology Dialysis Transplantation, 2012•academic.oup.comBackground. In the course of the influenza A H1N1 pandemic, transplanted patients were
recommended to receive vaccination. In the present study, we evaluated the immune
response to an adjuvanted influenza A H1N1 vaccine (Pandemrix®) in renal allograft
recipients. Methods. Sixty patients and 22 healthy controls participated in a prospective
observational study and received a single dose of Pandemrix®. H1N1 antibody titres as well
as anti-HLA antibodies were determined before and after vaccination. In 19 patients, a …
recommended to receive vaccination. In the present study, we evaluated the immune
response to an adjuvanted influenza A H1N1 vaccine (Pandemrix®) in renal allograft
recipients. Methods. Sixty patients and 22 healthy controls participated in a prospective
observational study and received a single dose of Pandemrix®. H1N1 antibody titres as well
as anti-HLA antibodies were determined before and after vaccination. In 19 patients, a …
Background
In the course of the influenza A H1N1 pandemic, transplanted patients were recommended to receive vaccination. In the present study, we evaluated the immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix®) in renal allograft recipients.
Methods
Sixty patients and 22 healthy controls participated in a prospective observational study and received a single dose of Pandemrix®. H1N1 antibody titres as well as anti-HLA antibodies were determined before and after vaccination. In 19 patients, a booster vaccination was performed and the outcome of all vaccinated renal allograft recipients (n = 107) in our clinic was reviewed.
Results
Two out of sixty patients had an elevated influenza A H1N1 titre before vaccination. Of the remaining 58 patients, only 20/58 (34.5%) developed a protective immune response in contrast to 20/22 (91%) of the control group. After booster vaccination, a protective titre was present in 8/19 (42%) of patients. Of the 107 patients, 6 (5.6%) developed new donor-specific HLA antibodies after vaccination.
Conclusions
These data suggest that Pandemrix® does not provide a protective immune response in the majority of kidney transplant recipients. Therefore, for new vaccines, efficacy as well as safety profiles should be evaluated in this subgroup of patients.
Oxford University Press